Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $17.25.

A number of research analysts have recently commented on the company. HC Wainwright dropped their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday. JMP Securities reiterated a "market outperform" rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Finally, Robert W. Baird dropped their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, November 26th.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the company's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter worth $35,000. US Bancorp DE raised its holdings in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares during the period. Quest Partners LLC raised its holdings in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $150,000 after acquiring an additional 9,692 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Enanta Pharmaceuticals in the third quarter valued at about $122,000. Finally, Valence8 US LP bought a new position in shares of Enanta Pharmaceuticals in the third quarter worth about $207,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA traded down $0.10 on Thursday, hitting $6.00. The stock had a trading volume of 388,499 shares, compared to its average volume of 225,887. The stock has a market cap of $127.16 million, a P/E ratio of -1.09 and a beta of 0.49. The firm's fifty day simple moving average is $9.40 and its two-hundred day simple moving average is $11.57. Enanta Pharmaceuticals has a 1 year low of $5.70 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm's revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.33) EPS. Equities research analysts predict that Enanta Pharmaceuticals will post -4.73 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.